“Aging is More than Sagging,” Dr. Corey Maas says, Associate Clinical Professor, University of California, San Francisco, New FDA Approved Product, Juvaderm Voluma XC™ Addresses Age-Related Volume Loss

As people age, the cheek area loses volume, making the cheeks flatten out and the skin droop and sag. Juvaderm Voluma XC™, just approved by the FDA, is the first and only filler approved to correct age-related volume loss in the cheek area. “This product will change the way we address facial aging and contouring,” says Dr. Maas.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

San Francisco, California (PRWEB) December 17, 2013

As people age, the cheek area loses volume, making the cheeks flatten out and the skin droop and sag. Juvaderm Voluma XC™, just approved by the FDA, is the first and only filler approved to correct age-related volume loss in the cheek area. “This product will change the way we address facial aging and contouring,” says Dr. Maas. It instantly provides smooth, natural-looking results that last up to two years with optimal correction.

With the FDA approval of Juvaderm Voluma XC™, physicians and patients in the U.S. now have a new treatment option that can help create a natural-looking, more youthful appearance in the cheek area. A very real alternative to surgical fat grafting or fat transfer sometimes referred to as “stem cell facelift.”

Dr. Maas welcomes the opportunity to discuss why and how the face loses volume as people age. I can also speak about how Juvaderm Voluma XC™ is an effective non-surgical treatment option for age-related volume loss in the cheek area.

Side effects are moderate (uncomfortable) and generally last 2 to 4 weeks. The most common side effects include temporary reactions at the treatment site such as tenderness, swelling, firmness, lumps/bumps, bruising, pain, redness, discoloration and itching. Juvaderm Voluma XC™ injectable gel is available by prescription only.

Currently FDA approved cosmetic injection products include the “stimulatory fillers,” Radiesse and Sculptra. Often used in facial lipoatrophy but do so through causing inflammation. Juvederm Volume XC is the first hyaluronic acid, (long chain sugar), product that is specifically manufactured to replace lost facial volume due to aging and certain diseases. This makes Juvaderm Voluma XC™ amongst the injectable fillers, a first non-inflammatory product.

Dr. Maas is an internationally recognized authority on cosmetic injections and surgery. He has published over 100 peer reviewed papers, book chapters and articles on the topic and has received awards and accolades for his ground-breaking advances in the field. The Research Center at The Maas Clinic has conducted numerous FDA clinical trials as pathway to approval of cosmetic injection products. An Associate Clinical Professor at The University of California, San Francisco, Dr. Maas has served as principal investigator on several FDA studies.

Additional information can be found at http://www.maasclinic.com or Facebook.com/maasclinic. Dr. Maas is immediately available for comment if you have further questions about the FDA approval of Juvaderm Voluma XC™ (http://www.juvederm.com/Views/voluma/).

Corey S. Maas, M.D. F.A.C.S.
The Maas Clinic
San Francisco – Lake Tahoe
Associate Clinical Professor
University of California, San Francisco
Phone 415.567.7000 530.582.7070
Fax 415.567.7011
http://www.Maasclinic.com
http://www.Drmaas.com


Contact

Attachments